# EDGAR Filing Document

**Accession Number:** 0001446847
**File Stem:** 0001104659-25-058883
**Filing Date:** 2025-6
**Character Count:** 5800
**Document Hash:** f9d685912b9d2787179846784f79da33
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-058883.hdr.sgml**: 20250612

**ACCESSION NUMBER**: 0001104659-25-058883

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20250610

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20250612

**DATE AS OF CHANGE**: 20250612

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** IRONWOOD PHARMACEUTICALS INC
- **CENTRAL INDEX KEY:** 0001446847
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 043404176
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-34620
- **FILM NUMBER:** 251042706

**BUSINESS ADDRESS:**
- **STREET 1:** 100 SUMMER STREET, SUITE 2300
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02110
- **BUSINESS PHONE:** 617-621-7722

**MAIL ADDRESS:**
- **STREET 1:** 100 SUMMER STREET, SUITE 2300
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02110

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**Current Report Pursuant to** 

**Section 13 or 15(d) of the** 

**Securities Exchange Act of 1934**

Date of Report (Date of Earliest Event Reported):

June 10, 2025

**IRONWOOD PHARMACEUTICALS, INC.**

*(Exact name of registrant as specified in its charter)*

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-34620** | **04-3404176** |
| *(State or other jurisdiction* | *(Commission File Number)* | *(I.R.S. Employer* |
| *of incorporation)* |  | *Identification Number)* |

---

---

| | |
|:---|:---|
| **100 Summer Street, Suite 2300** |  |
| **Boston, Massachusetts** | **02110** |
| *(Address of principal* | *(Zip code)* |
| *executive offices)* |  |

---

**(617) 621-7722**

*(Registrant's telephone number,*

*including area code)*

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

◻ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

◻ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

◻ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

◻ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which<br> registered |
| Class A common stock, $0.001 par value | IRWD | Nasdaq Global Select Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

On June 10, 2025, Ironwood Pharmaceuticals, Inc. (the "Company") held its 2025 Annual Meeting of Stockholders (the "Annual Meeting"). The final voting results for the Annual Meeting are as follows:

1. The stockholders elected nine director nominees, each to serve on the board of directors of the Company for a one-year term extending
until the 2026 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified, or until his or her death,
resignation or removal, based on the following votes:

---

| | | | |
|:---|:---|:---|:---|
| **Director Nominee** | **For** | **Withheld** | **Broker Non-Votes** |
| Mark Currie, Ph.D. | 110739267 | 2925704 | 17527704 |
| Alexander Denner, Ph.D. | 108426760 | 5238211 | 17527704 |
| Andrew Dreyfus | 110282918 | 3382053 | 17527704 |
| Jon Duane | 109604574 | 4060397 | 17527704 |
| Marla Kessler | 110720078 | 2944893 | 17527704 |
| Thomas McCourt | 110995716 | 2669255 | 17527704 |
| Julie McHugh | 109518572 | 4146399 | 17527704 |
| Catherine Moukheibir | 110936589 | 2728382 | 17527704 |
| Jay Shepard | 111094136 | 2570835 | 17527704 |

---

2. The stockholders approved, on a non-binding advisory basis, the compensation paid to the Company's named executive officers,
as disclosed in the Company's proxy statement for the Annual Meeting, based on the following votes:

---

| | | | |
|:---|:---|:---|:---|
| **For** | **Against** | **Abstain** | **Broker Non-Votes** |
| &nbsp;&nbsp;110,089,576 | &nbsp;&nbsp;3,511,070 | &nbsp;&nbsp;64,325 | &nbsp;&nbsp;17,527,704 |

---

3. The stockholders ratified the selection of Ernst & Young LLP as the Company's independent registered
public accounting firm for 2025, based on the following votes:

---

| | | | |
|:---|:---|:---|:---|
| **For** | **Against** | **Abstain** | **Broker Non-Votes** |
| &nbsp;&nbsp;128,241,210 | &nbsp;&nbsp;2,621,956 | &nbsp;&nbsp;329,509 | &nbsp;&nbsp;- |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Ironwood Pharmaceuticals, Inc.** | **Ironwood Pharmaceuticals, Inc.** |
| Dated: June 12, 2025 | By: | /s/ Gregory Martini |
|  |  | Name: Gregory Martini |
|  |  | Title: Senior Vice President, Chief Financial Officer |

---